Avenir Wellness Solutions, Inc.

OTCPK:AVRW Stock Report

Market Cap: US$3.9m

Avenir Wellness Solutions Past Earnings Performance

Past criteria checks 0/6

Avenir Wellness Solutions has been growing earnings at an average annual rate of 24.6%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 17.5% per year.

Key information

24.6%

Earnings growth rate

39.2%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate17.5%
Return on equityn/a
Net Margin-134.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Avenir Wellness Solutions makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:AVRW Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242-340
30 Jun 243-460
31 Mar 244-580
31 Dec 234-390
30 Sep 234-1180
30 Jun 235-590
31 Mar 235-14100
31 Dec 225-19100
30 Sep 225-1490
30 Jun 225-21100
31 Mar 226-1111-1
31 Dec 216-9140
30 Sep 216-23191
30 Jun 215-22171
31 Mar 213-36153
31 Dec 202-31113
30 Sep 201-1593
30 Jun 201-1093
31 Mar 201-9103
31 Dec 191-21102
30 Sep 191-2292
30 Jun 191-2992
31 Mar 191-1981
31 Dec 181-1061
30 Sep 180-1062
30 Jun 180-742
31 Mar 180-752
31 Dec 170-861
30 Sep 170-981
30 Jun 170-871
31 Mar 170-651
31 Dec 160-431
30 Sep 160-221
30 Jun 160-211
31 Mar 160-211
31 Dec 150-211
31 Dec 141-111

Quality Earnings: AVRW is currently unprofitable.

Growing Profit Margin: AVRW is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: AVRW is unprofitable, but has reduced losses over the past 5 years at a rate of 24.6% per year.

Accelerating Growth: Unable to compare AVRW's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AVRW is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).


Return on Equity

High ROE: AVRW's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies